At Nuevocor, our mission is to revolutionize the treatment of untreatable cardiomyopathies by embracing an innovative mechanobiology-centered approach. These conditions represent a pressing medical challenge, striking individuals at a relatively young age and leads to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
With operations in both Singapore and the United States, Nuevocor focuses on developing innovative first-in-class mechanobiology-based genetic medicines for heart conditions known as genetic cardiomyopathies.
Nuevocor’s lead program NVC-001 is a genetic medicine to treat patients suffering from lamin dilated cardiomyopathy.